ZERIT XR (nda021453)- (37.5MG,50MG,75MG,100MG)

Generic Name	STAVUDINE	Innovator	BRISTOL MYERS SQUIBB
Dosage	37.5MG,50MG,75MG,100MG
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	2023-Aug-18	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	ZERIT XR, in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
37.5MG	**	**	-	-	-
50MG	**	**	-	-	-
75MG	**	**	-	-	-
100MG	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of ZERIT XR